SBP <135 mm Hg Tied to Greater Mortality in Elderly With HTN

Share this content:
SBP &#60;135 mm Hg Tied to Greater Mortality in Elderly With HTN
SBP <135 mm Hg Tied to Greater Mortality in Elderly With HTN

WEDNESDAY, Jan. 4, 2017 (HealthDay News) -- For adults aged 80 years and older without comorbidity, systolic blood pressure (SBP) <135 mm Hg is associated with greater mortality, according to a study published online Dec. 30 in the Journal of the American Geriatrics Society.

João Delgado, Ph.D., from the University of Exeter Medical School in the United Kingdom, and colleagues conducted a cohort analysis among individuals (aged 80 years and older) who were taking antihypertensive medications, and were free of dementia, cancer, coronary heart disease, stroke, heart failure, and end-stage renal failure at baseline. The authors grouped SBP in 10-mm Hg increments from <125 mm Hg to ≥185 mm Hg (reference, 145 to 154 mm Hg)

The researchers observed a linear increase in the risk of myocardial infarction with increasing SBP. The risk of stroke increased for SBP of ≥145 mm Hg, while mortality was lowest among those with SBP of 135 to 154 mm Hg. For the 13.1 percent of participants with SBP <135 mm Hg, mortality was significantly higher than that seen in the reference group (hazard ratio, 1.25, equivalent to one extra death per 12.6 participants). This difference was consistent over short- and long-term follow-up and persisted after adjustment for diastolic BP.

"More work is needed to establish whether unplanned SBPs less than 135 mm Hg in older adults with hypertension may be a useful clinical sign of poor prognosis, perhaps requiring clinical review of overall care," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »